secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2022-04-06T23:59:59+00:00
Accession:  0001493152-22-009225
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic forms joint venture with Dragon Overseas; Dragon to invest $27.6M for 55% stake
--------------------------------------------------------------------------------

- Dragon Overseas invests $27.6M in cash and assets for 55% of JV; Oncotelic contributes OT-101 licenses for 45%.
- Oncotelic eligible for up to $50M from sale of RPD Priority Review Voucher for OT-101 (DIPG) after marketing approval.
- JV to develop TGF-β therapeutics, initially focusing on OT-101 for DIPG, pancreatic cancer, and glioblastoma.
- If Series A of ≥$20M not completed by Aug 31, 2022, Dragon's funding drops to $250K/month; licenses revert on termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315222009225/0001493152-22-009225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315222009225/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-009225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer